Back to Results

Clearside Biomedical Inc (CLSDQ)

Clearside Biomedical Inc. is a biopharmaceutical company listed on OTC Markets as common stock. The company focuses on developing therapies intended for delivery to the back of the eye through the suprachoroidal space. Its commercial product includes XIPERE, an injectable suspension used for macular edema linked to uveitis. Clearside also develops CLS-AX, an axitinib injectable suspension designed for suprachoroidal administration, which has completed a Phase 2 study in wet age-related macular degeneration. The company has reported collaboration arrangements with Bausch + Lomb Ireland Limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, BioCryst Pharmaceuticals, and Aura Biosciences. Incorporated in 2011 and headquartered in Alpharetta, Georgia, Clearside Biomedical filed a voluntary Chapter 11 reorganization petition in the U.S. Bankruptcy Court for the District of Delaware on November 23, 2025.


Stock Summary Fair Value Profitability & Growth Quality & Risk Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Price-to-Sales Ratio Market Cap Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-CLSDQ
Not available
Not available
Not available
Weak
5.4x
17.809 M
97.9%
87.7%
-50.6
83.7%
Valuation • Fair Value

Clearside Biomedical Inc (OTC-CLSDQ) Fair Value by Valuation Model

No usable valuation estimate is currently available for Clearside Biomedical Inc (OTC-CLSDQ); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Clearside Biomedical Inc (OTC-CLSDQ). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Clearside Biomedical Inc (OTC-CLSDQ)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

3.329 M

Current operating scale indicator.

Revenue Forecast

2.3 M

Forward revenue estimate.

EBITDA

-22.63 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Clearside Biomedical Inc (OTC-CLSDQ) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Clearside Biomedical Inc (OTC-CLSDQ)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-5.23

No elevated caution signal from this screen.

Altman Z-Score

-50.6

Lower score that deserves closer risk review.

FCF / Net Income

83.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Clearside Biomedical Inc (OTC-CLSDQ). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Clearside Biomedical Inc (OTC-CLSDQ) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Clearside Biomedical Inc (OTC-CLSDQ) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Clearside Biomedical Inc (OTC-CLSDQ) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Clearside Biomedical Inc (OTC-CLSDQ) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Clearside Biomedical Inc (OTC-CLSDQ) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Clearside Biomedical Inc (OTC-CLSDQ) Stock FAQ

Data-supported answers about Clearside Biomedical Inc (OTC-CLSDQ), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Weak
Current financial-health read

A reliable fair value estimate is not currently available for Clearside Biomedical Inc (OTC-CLSDQ). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Clearside Biomedical Inc (OTC-CLSDQ) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The current market capitalization listed for Clearside Biomedical Inc is 17.809 M.

The ticker symbol for Clearside Biomedical Inc is OTC-CLSDQ, and the stock is listed on OTC Markets.

Clearside Biomedical Inc (OTC-CLSDQ) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Clearside Biomedical Inc is 97.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Clearside Biomedical Inc is 87.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B